January 10, 2022
Company adds in vivo capabilities to existing ex vivo approach for development of novel gene therapies
Read MoreOctober 21, 2021
RDEB is a devastating, rare genetic blistering disease with no FDA-approved treatments currently available
Read MoreSeptember 29, 2021
Research to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments
Read MoreApril 20, 2021
Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial
Read MoreOctober 28, 2020
Company manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area
Read MoreOctober 15, 2020
Study targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.
Read MoreMarch 25, 2020
Leveraging proprietary technology and manufacturing platform to develop transformative gene therapies for multiple rare diseases with high unmet needs
Read More